Mauna Kea Technologies SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Mauna Kea Technologies SAS Announces That First Cellvizio Optical Biopsy Probe Designed for Urological Applications is Now CE Marked
Mauna Kea Technologies SAS announced that its UroFlex confocal miniprobe received CE mark approval for use during cystoscopy procedures. UroFlex is the first optical biopsy probe designed for urological applications and allows the company to enter the EUR 1 billion European urology device market. The new probe allows physicians to obtain optical biopsies that may facilitate the diagnosis, surveillance and treatment of patients with bladder cancer.
Latest Developments for Mauna Kea Technologies SA
- Mauna Kea Technologies SA regulatory clearance from U.S. FDA for New Cellvizio System Functioning in a near Infrared Wavelength
- Mauna Kea Technologies receives regulatory approval for Cellvizio in Japan
- Mauna Kea Technologies installs first three Cellvizio systems and obtains key regulatory clearances in Brazil
- Mauna Kea Technologies obtains FDA clearance for Cellvizio in urology
- Share this
- Digg this